Myeloma therapy: 25 years forward--immune modulation then and now
- PMID: 18779601
- DOI: 10.1200/JCO.2008.18.0109
Myeloma therapy: 25 years forward--immune modulation then and now
Similar articles
-
Mechanism of immunomodulatory drugs in multiple myeloma.Leuk Res. 2012 Oct;36(10):1218-24. doi: 10.1016/j.leukres.2012.05.010. Epub 2012 Jun 21. Leuk Res. 2012. PMID: 22727252 Review.
-
StatBite. Multiple myeloma: five-year relative survival.J Natl Cancer Inst. 2011 Jul 20;103(14):1084. doi: 10.1093/jnci/djr278. Epub 2011 Jul 7. J Natl Cancer Inst. 2011. PMID: 21737693 No abstract available.
-
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Expert Rev Hematol. 2012 Dec;5(6):617-26; quiz 627. doi: 10.1586/ehm.12.52. Expert Rev Hematol. 2012. PMID: 23216532 Review.
-
New oral anticoagulants might be useful thromboprophylactic agents in multiple myeloma patients on immunomodulatory agents.Blood Coagul Fibrinolysis. 2010 Dec;21(8):776-8. doi: 10.1097/MBC.0b013e328340142f. Blood Coagul Fibrinolysis. 2010. PMID: 21042059 No abstract available.
-
Immunomodulatory agents changing the landscape of multiple myeloma treatment.Crit Rev Oncol Hematol. 2013 Oct;88 Suppl 1:S1-4. doi: 10.1016/j.critrevonc.2012.12.011. Epub 2013 Jun 12. Crit Rev Oncol Hematol. 2013. PMID: 23769452 No abstract available.
Cited by
-
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.Haematologica. 2010 May;95(5):845-8. doi: 10.3324/haematol.2009.008003. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133895 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical